Tag: non-small-cell lung cancer

Results from a global Phase 3 trial demonstrated that trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) can delay disease progression longer than standard...

Gilead Accelerate Its Oncology ADC Pipeline by Acquiring Tubulis for $5B

Izalontamab Brengitecan Receives U.S. FDA Breakthrough Therapy Designation Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Preliminary results from the ongoing Phase 1 study (NCT06555744) evaluating ZW191, an antibody-drug conjugate (see ADC Drugmap) targeting folate receptor-alpha (FR⍺), were presented at...

Data from the dose escalation portion of the Phase 1/2 study of JK06 in patients with unresectable locally advanced or metastatic cancer, including non-small cell lung cancer (NSCLC) and breast cancer, is being presented at the European Society for Medical Oncology (ESMO) Congress, being held October 17 - 21, 2025, in Berlin, Germany.[1]

Daiichi Sankyo and Merck & CO/MSD have voluntarily withdrawn the Biologics License Application (BLA) seeking accelerated approval in the U.S. for patritumab deruxtecan (HER3-DXd) in patients with previously treated locally advanced or metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) previously treated with two or more systemic therapies.

During the upcoming annual meeting of the European Society for Medical Oncology (ESMO), being held in Barcelona, September 13-17, 2024, expect presentations to include new data on advances in the treatment of hard-to-treat cancers using approved and investigational agents, including enfortumab vedotin (Padcev™; Astellas/Pfizer/Seagen), Zolbetuximab (previously known as IMAB362), Enzalutamide (Xtandi®; Astellas/Pfizer) and various pipeline products.

Preclinical data highlighting the differentiating properties of Mythic Therapeutics' investigational cMET-targeting antibody-drug conjugates (ADC), MYTX-011, published in April 30, 2024 edition of Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR), demonstrated that this novel ADC which leverages Mythic’s innovative FateControl™ technology, actively navigated inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rinatabart sesutecan (Rina-S; PRO1184), a folate receptor alpha (FRα / FOLR1)...

Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in for Patients with Previously Treated Non-Small Cell Lung Cancer